Sanjay Gurunathan from Sanofi Pasteur, manufacturer of one of the vaccines used in RV144, said a new partnership of the US National Institute of Allergy and Infectious Diseases, The Bill & Melinda Gates Foundation, HIV Vaccine Trials Network, US Military HIV Research Program (MHRP), and Sanofi Pasteur — known as the Pox Protein Public Private Partnership, or P5 — will aim to
increase vaccine efficacy from the 31.2 percent of the RV144 trial to 50 percent.
One application of sieve analysis, once it's learned that a
vaccine's
efficacy depends on the genetics of the pathogen, is for the
vaccine manufacturer to add a different strain or strains to the
vaccine to
increase its protectiveness.